当新的fda批准的治疗方法不能广泛使用时，实验性基因治疗试验的招募和知情同意。

IF 17 1区哲学 Q1 ETHICS

American Journal of Bioethics Pub Date : 2025-04-01 Epub Date: 2025-04-07 DOI:10.1080/15265161.2025.2470671

Benjamin Slabaugh, Emily E Anderson

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Recruitment and Informed Consent for Experimental Gene Therapy Trials When New FDA-Approved Treatments are not Widely Available.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Bioethics 社会科学-科学史与科学哲学

CiteScore

12.30

自引率

26.90%

发文量

250

审稿时长

6-12 weeks

期刊介绍： The American Journal of Bioethics (AJOB) is a renowned global publication focused on bioethics. It tackles pressing ethical challenges in the realm of health sciences. With a commitment to the original vision of bioethics, AJOB explores the social consequences of advancements in biomedicine. It sparks meaningful discussions that have proved invaluable to a wide range of professionals, including judges, senators, journalists, scholars, and educators. AJOB covers various areas of interest, such as the ethical implications of clinical research, ensuring access to healthcare services, and the responsible handling of medical records and data. The journal welcomes contributions in the form of target articles presenting original research, open peer commentaries facilitating a dialogue, book reviews, and responses to open peer commentaries. By presenting insightful and authoritative content, AJOB continues to shape the field of bioethics and engage diverse stakeholders in crucial conversations about the intersection of medicine, ethics, and society.